TY - JOUR T1 - PCI does not improve outcomes for patients with stable angina JF - BMJ Evidence-Based Medicine JO - BMJ EBM SP - 71 LP - 72 DO - 10.1136/bmjebm-2018-110903 VL - 23 IS - 2 AU - Paul D Morris AU - David R Warriner Y1 - 2018/04/01 UR - http://ebm.bmj.com/content/23/2/71.abstract N2 - Commentary on: Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2017;391:31-40.More than 500 000 percutaneous coronary intervention (PCI) procedures are performed worldwide each year for stable coronary artery disease (CAD). In addition to medical therapy, physiologically targeted PCI reduces urgent revascularisation in this group1; however, unlike in acute coronary syndromes, evidence supporting a reduction in myocardial infarction and mortality is lacking,2 especially in those with low ischaemic burden.3 Consequently, in stable CAD, PCI is used predominantly for symptomatic relief. It is therefore remarkable that, 40 years after Andreas Grüntzig’s first PCI, we only now have results of the first double-blind, placebo-controlled trial of PCI in stable angina: the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) trial.4 Patients with stable angina and single-vessel … ER -